Blog

Elstar Therapeutics Closes $39M Series A Financing to Support Development of its Universal Targeted Immunotherapy … – Business Wire (press release)


FierceBiotech

Elstar Therapeutics Closes $39M Series A Financing to Support Development of its Universal Targeted Immunotherapy
Business Wire (press release)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Elstar Therapeutics, a company fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapies, today announced the closing of a $39M Series A
Big Pharma vets bag $39M to drive I/O firm Elstar forwardFierceBiotech



all 2 news articles »

2018-01-03 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.